Načítá se...
Bortezomib for refractory immune-mediated thrombocytopenia purpura (ITP)
The treatment of refractory immune-mediated thrombocytopenia (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteosome inhibitior. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura, but is a novel therapeutic appro...
Uloženo v:
| Vydáno v: | Am J Ther |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5753577/ https://ncbi.nlm.nih.gov/pubmed/29293474 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MJT.0000000000000517 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|